Penzberg, Germany, June 6 2013 / B3C newswire / - Roche today announced the global launch of new software updates, including advanced high- resolution melting analysis and qualitative detection modules for the LightCycler 96 and new support features for the LightCycler Nano system.
The new LightCycler 96 module for high- resolution melting analysis will be particularly valuable in human genetic disease research applications. It enables easy and fast detection of known and unknown gene mutations, including Single Nucleotide Polymorphisms, deletions and methylated regions. The novel dedicated qualitative detection module for LightCycler 96 enables direct detection and validation of a target gene´s presence or absence. This module also employs a novel control concept and is designed mainly for customers doing research in the field of infectious diseases.
The new features of the LightCycler Nano include advanced gene expression analysis mediated by the import of external standard curves. It also offers an enhanced analysis method for high- resolution melting experiments.
“The launch of these new software tools underlines our ongoing commitment to broadening the innovative features offered by our PCR systems,” said Gerd Haberhausen, Head of qPCR and Sample Preparation Systems. “We can build on almost 15 years of expertise in developing high-performance PCR systems that enable research breakthroughs for our customers around the world.”
Roche launched the LightCycler 96 System in October 2012 with a variety of analysis methods including endpoint genotyping and absolute and relative quantification. Data generated by the system can be analyzed directly or remotely for translation into publication-ready results in line with MIQE* guidelines. With the new software it will also be possible to create PDF or HTML reports.
The new software tools for the LightCycler 96 and LightCycler Nano systems will be supplied on a USB stick and will also be available to all customers for immediate download at www.lightcycler.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
LIGHTCYCLER is a trademark of Roche
All other product names and trademarks are the property of their respective owners.
For life science research only. Not for use in diagnostic procedures.
*MIQE: Minimum information required for publication of quantification experiments
For further information please contact:
Dr. Claudia Schmitt
Phone: +49 8856 60 10210